Literature DB >> 15492255

Progressive loss of Syk and abnormal proliferation in breast cancer cells.

Maria Moroni1, Viatcheslav Soldatenkov, Li Zhang, Ying Zhang, Gerald Stoica, Edmund Gehan, Banafsheh Rashidi, Baljit Singh, Metin Ozdemirli, Susette C Mueller.   

Abstract

The tumor suppressor gene Syk tyrosine kinase is absent or reduced in invasive breast cancer tissues and cell lines; its loss in breast tissues is linked to poor prognosis and metastasis. Also, evidence shows that in vitro Syk is involved in regulating proliferation. Here, we show by in situ hybridization on breast tissue sections that the loss of Syk expression is progressive during tumor development. Strikingly, Syk is already partially lost in normal epithelial tissue adjacent to the cancer lesion. In vivo, cell proliferation (as measured by the proliferative index Ki67) increased from normal to ductal carcinoma in situ to invasive, whereas Syk in situ staining in the same tissues decreased. In vitro, the presence of Syk was associated with reduced cell proliferation in an epidermal growth factor receptor-overexpressing breast cancer cell line, BT549, whereas changes in apoptosis were undetected. Concomitantly, the kinase activity of the proto-oncogene Src was reduced by approximately 30%. A 5-fold increase in abnormal mitoses was observed in the Syk-transfected cells compared with vector control. We propose that Syk is involved in the regulation of cell proliferation, possibly by controlling mechanisms of mitosis and cytokinesis via Src signal transduction pathway(s). Because of its progressive and early loss during tumor onset and development, monitoring of Syk loss in breast epithelial cells by noninvasive techniques such as ductal lavage may be a powerful tool for screening purposes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492255     DOI: 10.1158/0008-5472.CAN-03-3520

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer.

Authors:  Junjie Peng; Zhimin Wang; Wei Chen; Yin Ding; Haifeng Wang; Hongjie Huang; Wei Huang; Sanjun Cai
Journal:  Int J Colorectal Dis       Date:  2010-08-13       Impact factor: 2.571

2.  In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers.

Authors:  Anton B Iliuk; Victoria A Martin; Bethany M Alicie; Robert L Geahlen; W Andy Tao
Journal:  Mol Cell Proteomics       Date:  2010-06-17       Impact factor: 5.911

3.  Differential expression of spleen tyrosine kinase Syk isoforms in tissues: Effects of the microbial flora.

Authors:  Florentina Duta; Marina Ulanova; Daniel Seidel; Lakshmi Puttagunta; Sorin Musat-Marcu; Kevin S Harrod; Alan D Schreiber; Ulrich Steinhoff; A Dean Befus
Journal:  Histochem Cell Biol       Date:  2006-05-18       Impact factor: 4.304

4.  Syk kinase as a treatment target for therapy in autoimmune diseases.

Authors:  Vasileios C Kyttaris; George C Tsokos
Journal:  Clin Immunol       Date:  2007-07-26       Impact factor: 3.969

5.  Migration inhibition of mammary epithelial cells by Syk is blocked in the presence of DDR1 receptors.

Authors:  Brit Neuhaus; Sebastian Bühren; Barbara Böck; Frauke Alves; Wolfgang F Vogel; Friedemann Kiefer
Journal:  Cell Mol Life Sci       Date:  2011-04-17       Impact factor: 9.261

6.  Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival.

Authors:  Wen-Horng Wang; Michael O Childress; Robert L Geahlen
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

7.  Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.

Authors:  Olivier Bailet; Nina Fenouille; Patricia Abbe; Guillaume Robert; Stéphane Rocchi; Nadège Gonthier; Christophe Denoyelle; Michel Ticchioni; Jean-Paul Ortonne; Robert Ballotti; Marcel Deckert; Sophie Tartare-Deckert
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

8.  Syk inhibits the activity of protein kinase A by phosphorylating tyrosine 330 of the catalytic subunit.

Authors:  Shuai Yu; He Huang; Anton Iliuk; Wen-Horng Wang; Keerthi B Jayasundera; W Andy Tao; Carol B Post; Robert L Geahlen
Journal:  J Biol Chem       Date:  2013-02-27       Impact factor: 5.157

9.  The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.

Authors:  Q Zhou; R L Geahlen
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

10.  Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo.

Authors:  You Me Sung; Xuehua Xu; Junfeng Sun; Duane Mueller; Kinza Sentissi; Peter Johnson; Elana Urbach; Françoise Seillier-Moiseiwitsch; Michael D Johnson; Susette C Mueller
Journal:  PLoS One       Date:  2009-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.